A Phase 2 interventional study of KAI-7535 and Placebo in Obesity and Overweight, sponsored by Kailera. Active, not recruiting at 36 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by Kailera · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to determine the efficacy of oral KAI-7535 once daily compared with placebo on percent change in body weight in participants living with obesity or overweight, with at least 1 weight-related comorbidity, without diabetes mellitus. Safety and tolerability and other weight-related outcomes will also be evaluated.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
This study's enrollment of 306 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Browse Obesity studies →Kailera is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
For participants without diabetes mellitus at screening and on Day 1, ≥30 kilograms/square meter (kg/m\^2) or BMI ≥27 kg/m\^2 and a previous diagnosis of at least 1 of the following:
For participants living with type 2 diabetes mellitus and BMI ≥27 kg/m\^2 only:
Key Exclusion Criteria:
For participants without diabetes:
For participants living with type 2 diabetes mellitus only:
Note: Additional inclusion/exclusion criteria may apply, per protocol.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive KAI-7535 once daily.
Drug: KAI-7535
Participants will receive KAI-7535 once daily.
Drug: KAI-7535
Participants will receive KAI-7535 once daily.
Drug: KAI-7535
Participants will receive KAI-7535 once daily.
Drug: KAI-7535
Participants will receive placebo matched to KAI-7535 once daily.
Drug: Placebo
Oral tablets
Oral tablets
Percent Change from Baseline in Body Weight at Week 44 for Participants Without Diabetes Mellitus
Time frame: Baseline, Week 44
Change from Baseline in Body Weight at Week 44
Time frame: Baseline, Week 44
Change from Baseline in Body Mass Index (BMI) at Week 44
Time frame: Baseline, Week 44
Percentage of Participants at Week 44 with ≥5% and ≥10% Reduction in Body Weight
Time frame: Week 44
Change from Baseline in Waist Circumference at Week 44
Time frame: Baseline, Week 44
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Jul 2027, 15 months after the start.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 15 months is above that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kailera